Taiwan Bulk Drug Production Drives Healthy First Five Months
This article was originally published in PharmAsia News
Executive Summary
Taiwan's bulk-drug production increased by more than a third for the first five months of this year, leading to an overall 6.7 percent increase in pharmaceutical production, according to Industry and Technology Intelligence Services. During the period, ITIS said, the value of the production rose to $759.2 million. Production of Western pharmaceuticals rose only 0.9 percent between January and May, the poor growth rate blamed on government policy that adjusted co-payments for drugs from that sector. An ITIS analyst said he expected the industry's overall production to continue to experience stable growth for the rest of this year, led again by an expected surge in active pharmaceutical ingredients exports. (Click here for more
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.